Sonic Healthcare (STU:SAB) Moat Score: 5/10 (As of Jul. 04, 2026)


STU:SAB Sonic Healthcare Ltd STU:SAB
69 GF Score
Price €12.61
GF Value €19.60
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sonic Healthcare Moat Score?

Sonic Healthcare STU:SAB +0.69% 69 Moat Score is 5 as of Jul. 04, 2026. GuruFocus rates STU:SAB with a GF Score™ of 69/100 and a GF Value™ of €19.60 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Sonic Healthcare ranks better than 87.5% on this metric.

Sonic Healthcare has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Sonic Healthcare has Narrow Moat: Sonic Healthcare Ltd has a solid narrow moat with strong brand recognition and customer loyalty in medical diagnostics. It benefits from regulatory barriers and economies of scale, but lacks the dominance needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sonic Healthcare might have Narrow Moat - Solid narrow moat.

Sonic Healthcare  (STU:SAB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sonic Healthcare Moat Score Related Terms

STU:SAB vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Sonic Healthcare's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonic Healthcare Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sonic Healthcare's Moat Score distribution charts can be found below:

* The bar in red indicates where Sonic Healthcare's Moat Score falls into.


STU:SAB
69GF Score
Sonic Healthcare Ltd STU:SAB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Sonic Healthcare (STU:SAB) has a Moat Score of 5 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sonic Healthcare ranks #27 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 12.5%.
Is Sonic Healthcare's Moat Score too high?
Sonic Healthcare's current Moat Score is 5. Based on the distribution chart, Sonic Healthcare ranks #27 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sonic Healthcare has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonic Healthcare's Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sonic Healthcare ranks #27 out of 216 companies for Moat Score. This places Sonic Healthcare in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sonic Healthcare's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sonic Healthcare (STU:SAB) is currently considered Significantly Undervalued. The stock's GF Value™ is €19.60, compared to a current price of €12.61 — trading 35.7% below its estimated fair value. The current Moat Score is 5. Sonic Healthcare's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sonic Healthcare (STU:SAB), the current Moat Score is 5 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sonic Healthcare (STU:SAB) Overvalued in 2026?

Based on GuruFocus' analysis, Sonic Healthcare stock appears to be undervalued. The current stock price of €12.61 is trading 35.7% below its estimated GF Value™ of €19.60. GuruFocus considers Sonic Healthcare to be Significantly Undervalued.

Key valuation signals for STU:SAB:

  • Moat Score: 5
  • GF Value™: €19.60 vs. price of €12.61 (35.7% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:SAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sonic Healthcare Business Description

Address 225 George Street, Level 22, Grosvenor Place, Sydney, NSW, AUS, 2000
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe.
69GF Score

Get the complete analysis for STU:SAB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.61
Price
€19.60
GF Value